GENSIA SIGNS EXCLUSIVE U.S. DISTRIBUTION AGREEMENT FOR NEW ANESTHESIOLOGY PRODUCT
GENSIA SIGNS EXCLUSIVE U.S. DISTRIBUTION AGREEMENT
FOR NEW ANESTHESIOLOGY PRODUCT
SAN DIEGO, Sept. 22 /PRNewswire/ -- Gensia Pharmaceuticals, Inc. (NASDAQ: GNSA) today announced that it has acquired from Intavent International S.A. (Intavent) the exclusive U.S. distribution rights to the laryngeal mask airway (LMA), a product for maintaining an open airway in surgical patients receiving general anesthesia. Gensia expects to introduce the LMA to the U.S. market in October 1992 through its Gensia Laboratories, Ltd. subsidiary, according to David F. Hale, chairman, president and chief executive officer.
The LMA is designed to provide an alternative to a face mask or an endotracheal tube when administering general anesthesia. The LMA, which Gensia believes has been used in more than 2.5 million surgical procedures in the United Kingdom since its introduction in 1988, has not previously been marketed in the U.S.
"We expect the LMA to promote market awarenesss of Gensia Laboratories' other anesthesiology products," said Hale. "In addition, the LMA will provide our sales force with an opportunity to begin marketing to anesthesiologists, who are expected to be a primary physician prescribing group for Arasine, assuming Arasine is approved for marketing in the U.S. by the Food and Drug Adminsitration."
The LMA is a reusable device designed to be less traumatic to the patient. The LMA avoids many of the problems associated with laryngoscopy and intubation and reduces post operative throat soreness common with the use of an endotracheal tube. It also allows the anesthesiologist to maintain an open airway without manual maintenance, leaving the anesthesiologist free to attend to patient monitorning and record keeping.
Gensia Laboratories, a wholly owned subsidiary of Gensia Pharmaceuticals, is located in Irvine, Calif. and manufactures and markets multisource injectable drug products for the acute-care, hospital market. Gensia Pharmaceuticals is a San Diego-based biopharmaceutical company formed to discover, develop, manufacture and market novel pharmaceutical products for the treatment and diagnosis of human diseases.
/CONTACT: Martha L. Hough or Elizabeth A. Gard of Gensia Pharmaceuticals, Inc., 619-546-8300/
(GNSA) CO: Gensia Pharmaceuticals, Inc. ST: California IN: MTC SU: SB -- NY013 -- 2158 09/22/92 12:00 EDT